КЛИНИЧЕСКИЕ АСПЕКТЫ СОЧЕТАНИЯ COVID-19 И ХРОНИЧЕСКИХ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ – СОБСТВЕННЫЙ ОПЫТ

Abstract

We conducted a cohort prospective open study to evaluate the impact of COVID-19 on the course of chronic pulmonary disease (CPD). The study enrolled 68 CPD patients after COVID-19. We analyzed patients’ complaints, life histories, bronchopulmonary disease records, comorbidity records, examination records, archived data of multispiral CT (MSCT) of the chest. CPD included sarcoidosis of intrathoracic lymph nodes (ITLN) and pulmonary sarcoidosis (36.7%), chronic obstructive pulmonary disease (COPD) (30.9%), bronchial asthma (BA) (17.6%). Other CPD were rare – hypersensitivity pneumonitis (5.8%), bronchiectatic lung disease (5.8%), rheumatoid lung disease (2.9%). We did not establish any association between the nosological form of CPD and the need for hospitalization for COVID-19. According to MSCT data, most patients (61%) had signs of viral pneumonia. The comparative analysis of viral lesion in the lungs (by MSCT data) did not detect any correlation between this specific parameter and the nosological form of CPD. We did not detect any correlation between the nosological form of CPD and the frequency of viral pneumonia. The analysis of CPD exacerbation frequency during 1–3 and 3–6 months after COVID-19 showed that exacerbations occurred in 63.2% of patients, mostlduring 1–3 months after COVID-19 (50% of patients vs. 13.2% of patients during 3–6 months). The differences in exacerbation frequencies during 1–3 months vs. 3–6 months after COVID-19 were only statistically significant in patients with COPD or BA. In the post-COVID-19 period (one through 12 months) the most frequent complaints (67.6%) were weakness, cough, and dyspnea of different degrees.